Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Operations: 2019-2024

Historic Cash from Operations for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$134.6 million.

  • 4D Molecular Therapeutics' Cash from Operations fell 58.20% to -$46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 61.85%. This contributed to the annual value of -$134.6 million for FY2024, which is 77.57% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Cash from Operations stood at -$134.6 million for FY2024, which was down 77.57% from -$75.8 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Cash from Operations registered a high of -$50.9 million during FY2020, and its lowest value of -$134.6 million during FY2024.
  • In the last 3 years, 4D Molecular Therapeutics' Cash from Operations had a median value of -$86.7 million in 2022 and averaged -$99.0 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Cash from Operations rose by 12.57% in 2023, and later slumped by 77.57% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Cash from Operations (Yearly) stood at -$50.9 million in 2020, then slumped by 35.80% to -$69.1 million in 2021, then decreased by 25.39% to -$86.7 million in 2022, then climbed by 12.57% to -$75.8 million in 2023, then slumped by 77.57% to -$134.6 million in 2024.